COPD is a chronic inflammatory respiratory condition, characterized by progressive airflow limitation that is not fully reversible. The accelerated deterioration of pulmonary function may occur at any stage in the course of the disease. The associated episodes are called acute exacerbations of COPD (AECOPD). Frequent exacerbations hasten lung function decline, affecting quality of life, exercise capacity, and survival in patients with COPD. 1 Although exacerbations are key events in the progression of COPD, little information is available regarding the mechanism by which exacerbations may contribute to airway remodeling and associated structural changes in lung tissue. In this respect, it has been shown that chronic inflammation in COPD and exacerbations are associated with disturbances in the homeostasis of extracellular matrix (ECM) molecules. 2, 3 The ECM of the lung consists mainly of collagens, elastin, and proteoglycans, and it is subjected to a daily turnover of approximately 10%, indicating that subtle changes in turnover rates lead to large changes in total ECM composition with time. The interstitial matrix is the main local area affected by inflammation and is mainly composed of collagen type I and collagen type III as well as collagen type VI. [4] [5] [6] [7] [8] The main protein of the lung is elastin, which is responsible for the elastic properties of the lung tissue. It has been found that the remodeling of elastin in healthy states is very low, with a half-life of approximately 15 years; however, this level seems to be elevated in pulmonary diseases. 9, 10 Matrix metalloproteinase (MMP)-2 and -9 have been implicated in the degradation of ECM components such as collagen type I, collagen type III, collagen type VI, as well as elastin, and are expressed by inflammatory cells such as macrophages. [8] [9] [10] [11] [12] With tissue inflammation, MMP expression and proteolytic activity are upregulated, causing protein fragments to be released into the circulation, where they may serve as ECM-specific biomarkers. Assessment of lung ECM protein fragments, also known as neoepitopes, may therefore provide novel biomarkers for disease exacerbation, prognosis, and activity.
We recently investigated key ECM molecules of the lung, such as MMPs, tissue inhibitors of metalloproteinases (TIMPs), and glycosaminoglycans. We found that levels of MMP-9, TIMP-1, TIMP-2, heparan sulfate, and chondroitin sulfate were significantly increased in BAL fluid (BALF) of patients with COPD during exacerbations. 13, 14 Levels of heparan sulfate and chondroitin sulfate are significantly correlated with MMP-9, MMP-2, and MMP-12 in BALF, indicating that they were cleaved from their respective proteoglycans by MMPs and subsequently washed out in BALF. Moreover, a significant turnover of hyaluronic acid was observed in BALF during exacerbations. 15 These data indicate that during AECOPD, there is an increased turnover of ECM molecules, which may be associated with airway remodeling and lung function decline during exacerbations of COPD.
In the present study, we hypothesized that systemic biomarkers of ECM protein degradation and formation, reflecting ECM turnover, are increased during COPD exacerbations and that ECM activity is associated with disease severity and outcome in COPD.
Materials and Methods

Study Design and Patients
Data from two independent cohorts were analyzed in the present study. The confirmation cohort consisted of 638 patients enrolled in the Predicting Outcome Using Systemic Markers in Severe Exacerbations of Chronic Obstructive Pulmonary Disease (PROMISE-COPD) trial, a multicenter study in 11 centers in eight European countries that evaluated the potential predictors of outcome in patients with moderate to very severe COPD. The PROMISE-COPD study was designed to be inclusive, exploratory, and hypothesis-generating, and it was specifically drafted to identify predictors of outcome by using systemic markers in COPD. All enrolled patients had an initial baseline examination at stable state and were followed up for at least 2 years in scheduled half yearly visits. When necessary, patients underwent outpatient visits or were hospitalized for treatment of AECOPD, and follow-up visits were performed 4 weeks after the onset of exacerbation. Throughout the study duration, patients were treated as clinically warranted, without restriction. Patients were monitored for recurrent moderate (requiring treatment with systematic corticosteroids, antibiotics, or both) and severe (requiring hospitalization or a visit to the ED) AECOPD. Of the 638 patients, 506 attended a scheduled visit at 6 months and were therefore eligible for inclusion in the subsequent analyses. Clinical history, physical examinations, lung function, and 6-min walking test were performed for each patient. 16 The age-adjusted Charlson Comorbidity Index score was also calculated for patients included in the confirmation cohort. Each patient completed the following: the Modified Medical Research Council Score (MMRC); the St. George's Respiratory Questionnaire (SGRQ) COPD version; and the 36-item Short-Form Health Survey (SF-36), a health-related, quality of life questionnaire. All examinations took place at each scheduled visit (semi-annually), except for the 6-min walking test. At the 2-year follow-up, the vital status of each patient was confirmed.
The derivation cohort consisted of 100 patients included in the Basel Study on COPD (BASCO), a cross-sectional, observational, monocentric study that included patients with COPD undergoing bronchoscopy for clinical indications. Serum samples, at stable state, were collected at the day of bronchoscopy. In the confirmation cohort, serum samples were collected at stable state, at exacerbation, and at exacerbation follow-up (4 weeks after exacerbation).
A control group was also included that consisted of 56 unselected, consecutive healthy blood donors. Serum samples from the control group were treated identically with serum samples from the derivation and the confirmation cohorts.
For both studies, patients with COPD were categorized as Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade II to IV. BASCO and PROMISE-COPD were investigator-initiated and -driven studies, compiled according to the Declaration of Helsinki and Good Clinical Practice Guidelines, and were approved by the institutional review board (EKBB05/06 and EKBB295/07). The PROMISE-COPD study was registered at www.controlled-trials.com (identifier ISRCTN99586989). All patients provided written consent before initiation of any study assessments. A detailed description of the two cohorts is provided in e-Appendix 1.
Determination of Biomarkers
Serum levels of fragments of collagen type III (C3M) and collagen type VI (C6M) pro-forms of collagen type III (Pro-C3) and type VI (Pro-C6), and neutrophil elastase-generated fragments of elastin (EL-NE) were measured by using Nordic Bioscience assays according to the manufacturer's instructions. 17 All assays used a monoclonal antibody directed against either a protein fragment produced by protease cleavage during degradation or formation, or an internal protein sequence, as described previously. 17 All serum samples were assayed in duplicate, in a single run by personnel unaware of the patients' clinical data. Values of biomarkers were divided into quartiles for data analyses. 
Statistics
Results
ECM Biomarkers in Patients With COPD
In the PROMISE-COPD cohort, most patients were male and had a considerable smoking history, clinically relevant disease (1 exacerbation requiring physician attention in the previous year) ( Table 1) , and multiple comorbidities (e-Table 1). Patients were followed up for a median of 722 days (interquartile range, 395-762 days). During the follow-up, 317 patients (62.6%) experienced $ 1 exacerbation (354 exacerbations in total), and 38 patients died (7.5%) (Fig 1) . Characteristics of the 354 exacerbations are presented in Table 2 . The demographic characteristics of the 100 patients included in the derivation cohort in stable state are depicted in e- Table 2 .
We first investigated the association between the circulating biomarkers of ECM turnover and severity of airflow limitation as assessed according to GOLD grades. In the PROMISE-COPD cohort, a significant association was observed between collagen type III and collagen type VI turnover and disease severity (Table 3) . These data confirmed the observations obtained in the BASCO-COPD cohort (e- Table 3 ).
We further investigated the association of the circulating biomarkers of ECM turnover with lung function as assessed by FEV 1 % predicted and FEV 1 /FVC. In the PROMISE-COPD cohort, C3M, C6M, Pro-C3, Pro-C6, and EL-NE were associated with the FEV 1 % predicted (Table 4) . Similarly, there was an association of Pro-C3 and Pro-C6 with airflow limitation as expressed by the FEV 1 /FVC. Most of the aforementioned associations were also evident in the BASCO-COPD cohort (e- Table 4 ).
In the PROMISE-COPD cohort, patients with lower levels of Pro-C3 had more severe airflow limitations (FEV 1 and FEV 1 /FVC), hyperinflation (total lung capacity), air trapping (residual volume/total lung capacity), and emphysema (diffusion capacity) compared with patients with higher circulating levels journal.publications.chestnet.org of Pro-C3 (Fig 2A) . Patients with lower levels of Pro-C6 had more severe hyperinflation, air trapping, and emphysema ( Fig 2B) . These observations were also reported in the BASCO-COPD cohort (data not shown).
We further analyzed the effect of inhaled corticosteroids (ICS) on epitope concentrations in the PROMISE-COPD cohort. C3M, C6M, and EL-NE were significantly higher (P ¼ .004, P ¼ .010, and P ¼ .040, respectively) and Pro-C3 was significantly lower (P ¼ .047) in patients receiving ICS compared with patients who did not receive ICS. However, when a linear regression analysis was performed (adjusted for FEV 1 % predicted), we found that only C6M remained significantly higher (P ¼ .02) in patients receiving ICS.
ECM Biomarkers and Disease Impact
To investigate the influence of ECM biomarkers on disease impact, we evaluated their levels according to the degree of dyspnea as assessed by using the MMRC. In the PROMISE-COPD cohort, C3M, C6M, and EL-NE levels differed significantly according to the degree of dyspnea (geometric mean ratio, 1.25 [1.13-1.14], 1.38 [1.18-1.62], and 1.47 [1.14-1.90], respectively; all, P < .0001). C6M and Pro-C6 were associated with the exercise capacity (geometric mean ratios of 0.999 No. of exacerbations in previous year
No. of severe exacerbations in previous year Results of body plethysmography (residual volume, total lung capacity, residual volume/total lung capacity, and diffusion capacity), as well as ABGA (oxygen pressure and CO 2 pressure), were collected for 257 patients of a predefined nested cohort. Overall, Pro-C3 presented the strongest association with the health-related quality of life (SGRQ) and physical function domain of the SF-36 according to the distribution of Pro-C3 in quartiles (Q 1 vs Q 2 -Q 4 ), at stable state (Fig 3, Table 5 ). Patients with the lowest levels of Pro-C3 had the poorest health-related quality of life in all the domains as assessed by using the SGRQ and the worst physical function in the SF-36.
ECM Biomarkers and Bacterial Colonization
In the PROMISE-COPD cohort, 155 patients (30.6%) at the stable state visit were able to produce sputum of good quality for microbiologic analysis. Forty-eight of these samples (30.9%) demonstrated potentially pathogenic bacteria growth. These patients, with verified bacterial colonization in sputum, had elevated C3M (33.2 ng/mL [26.9- 
ECM Biomarkers at Exacerbation
We further investigated if serum levels of ECM biomarkers were higher in patients with COPD compared with non-COPD control subjects. As shown in Table 6 , levels of C3M, C6M, Pro-C6, EL-NE, Pro-C3/ C3M, and Pro-C6/C6M were higher in patients with COPD compared with the control subjects.
To investigate if circulating levels of ECM biomarkers were altered between stable state and exacerbations of COPD, we measured their serum levels in patients of the PROMISE-COPD cohort at stable state, at exacerbation, and at 4 weeks after exacerbation (Fig 4) . Except for Pro-C3, ECM biomarkers differed significantly between stable state and exacerbation in the crude and adjusted analyses (C3M, P ¼ 0.02; all others, P < .001). Four weeks after exacerbation, values for C3M, C6M, and Pro-C6 returned to values obtained at stable state of the disease. EL-NE remained increased 4 weeks after exacerbation in the crude and adjusted analyses (P ¼ .002 and P ¼ .005). After adjustment for the clinical model (ie, sex, BMI, FEV 1 % predicted), circulating levels of C6M differed between exacerbation follow-up and stable state (P ¼ .04).
Upon dichotomization, C6M, Pro-C6, and EL-NE were increased both in the moderate and severe exacerbations compared with the stable state before and after adjustment. C3M was consistently increased only in severe exacerbations. Pro-C3 was not associated with moderate or severe exacerbations in the crude and adjusted analyses.
Degradation and formation balance of collagen type VI (Pro-C6/C6M) differed at stable state and exacerbation, journal.publications.chestnet.org both moderate and severe, before and after adjustment for the clinical model (P < .001 for all). In contrast, the turnover of collagen III (Pro-C3/C3M) was similar at stable state and exacerbation in all models.
ECM Biomarkers and Disease Outcome
Patients experiencing an exacerbation during the 2-year follow-up had significantly lower levels of Pro-C3 and Pro-C6 (P < .001 and P ¼ .001) and EL-NE (P ¼ .041) at stable state compared with patients who did not have an exacerbation during the 2-year follow-up (Fig 5A) . Levels for C3M and C6M did not differ between survivors and nonsurvivors (Fig 5B) To demonstrate the potential predictive value of Pro-C6 that was found to be the best predictor of survival, a receiver operating-characteristic curve analysis was performed. As shown in Figure 6 , survival of patients up Signs of right-heart failure, % 4 (1.2) (Continued) to 2 years differed significantly between patients with Pro-C6 at stable state above or below the median for both the crude analysis (P ¼ .0241) and the adjusted analysis (P ¼ .028).
Discussion
We have previously shown that ECM turnover plays a major role in the lung function loss associated with recurrent exacerbations. [13] [14] [15] In the present study, we used recently developed assays to assess the levels of circulating neoepitopes for the systematic evaluation of the turnover of collagen type III, collagen type VI and elastin (molecules that have a paramount function in maintaining lung architecture) in two independent COPD cohorts. We showed that alterations in collagen and elastin metabolism were associated with lung function impairment (airflow limitation, hyperinflation, air trapping, and emphysema), disease severity (dyspnea, exercise capacity, and health-related quality of life), and bacterial colonization in stable COPD. The longitudinal assessment of circulating ECM markers at three points in time strongly suggests an increase in the activity of proteolytic enzymes at exacerbation, followed by a subsequent decrease to pre-exacerbation levels after 4 weeks. These neoepitopes, most likely generated by MMPs, were also found to be predictive for recurrence of exacerbation and survival in COPD. The associations with exacerbation and outcome proved to be independent of age, sex, extent of dyspnea, grade of airflow limitation, and comorbidities. To our knowledge, this study is the largest showing that ECM turnover, as assessed by using circulating neoepitope levels, is associated with disease severity, exacerbations, and survival in COPD.
All measured circulating markers of ECM turnover were associated with airflow limitations in the present study. Although degradation fragments of collagen type III and collagen type VI increased in patients with moderate to severe COPD, formation markers of collagen type III and collagen type VI presented the opposite behavior. These results suggest that there is an increase in turnover of collagen type III and collagen type VI parallel to an increase in COPD severity, as assessed according to lung function. The association between lung function and C3M, C6M, Pro-C6, and EL-NE was Collagen type III is an abundant ECM protein in the lung, and it has a paramount function in maintaining lung architecture. Furthermore, collagen type VI fibrils, together with other collagens and fibronectin, support tissue structure by adhering to the interstitial matrix. Thus, the interstitial matrix turnover seems to increase in parallel to disease severity in COPD. Interestingly, patients with the lowest levels of formation fragments of collagen type III and collagen type VI had more hyperinflation, air trapping, and emphysema. In our view, these differences, particularly for the diffusion capacity and residual volume, are of clinical relevance. This is the first time that systemic markers of degradation and formation of collagen type III and collagen type VI were associated with parameters obtained by using body plethysmography in COPD. Our results indicate that a deficient formation of collagen type III and collagen type VI may result predominantly in enhanced proteolysis in the stroma of pulmonary tissue.
We also found that C3M, C6M, and EL-NE levels were associated with the MMRC score. This finding disagrees with results of a previous report. 18 Taken together with the more severe impairment in the health-related quality of life observed in patients with increased collagen type VI degradation, this result seems plausible. Similarly, patients with decreased formation of collagen type III had the poorest health-related quality of life and the worst physical function, findings that match with the more severe impairment in lung function. This is the first time that health-related Figure 4 -Serum levels of C3M, Pro-C3, C6M, Pro-C6, and EL-NE at stable state (N ¼ 506), at exacerbation both moderate (n ¼ 234) and severe (n ¼ 115), and at follow-up of exacerbation (n ¼ 104) adjusted for the clinical model. ***P < .001, **P < .01, *P < .05. C3M ¼ fragments of collagen type III; C6M ¼ fragments of collagen type VI; EL-NE ¼ neutrophil elastase-generated fragments of elastin; Pro-C3 ¼ pro-forms of collagen type III; Pro-C6 ¼ pro-forms of collagen type VI. formation of collagen type VI; and no change in collagen type III formation at exacerbation. Due to the large sample size and comprehensive clinical characterization, we could also establish that these differences remained unaffected after adjustment in the clinical model. We found that degradation and formation of collagen type VI and EL-NE were increased both in moderate and severe exacerbations, whereas degradation of collagen type III was only increased in severe exacerbations. In contrast to previous data, 19 we found a difference in degradation and formation ratio for collagen type VI but not for collagen type III at exacerbation.
Most extracellular collagens are initially degraded by MMPs (including MMP-1, -3, -7, -8, -13, -14, -16, and -18) that generate collagen fragments, which are further digested by MMP-2 and MMP-9. 22 Neoepitope fragments of collagen type II and collagen type III generated by MMPs have been shown to reflect disease activity in rheumatoid arthritis and to predict response to anti-IL-6 treatment with tocilizumab. 23 Similarly, related markers such as MMP-generated neoepitopes of collagen type I and collagen type VI have been discussed as appropriate markers for disease activity in idiopathic pulmonary fibrosis.
24
It remains to be clarified if the increased levels of C3M and C6M that we report in the present study reflect increased serum levels or increased activity of MMPs. In this context, these results agree with the increased levels of MMP-9, TIMP-1, TIMP-2, heparan sulfate, chondroitin sulfate, and hyaluronic acid in the BAL at exacerbation that we have previously described. [13] [14] [15] An additional new finding is that, except for EL-NE, levels of C3M, C6M, and Pro-C6 returned to basal levels measured at stable state within 4 weeks after exacerbation. These results indicate that the ECM turnover associated with exacerbations in COPD was an acute event and that there are repair mechanisms which contribute to balancing the increased degradation of ECM within 4 weeks following exacerbations of COPD. We must still determine if the structural changes that 024 Figure 6 -Receiver-operating characteristic curve analysis for pro-forms of collagen type VI, the best predictor for survival, dichotomized at the median at stable state. P ¼ .0241 for the crude analysis and P ¼ .028 for the analysis adjusted for the clinical model.
journal.publications.chestnet.org result from the ECM turnover remain in the stroma of pulmonary tissue after each exacerbation. The elevated levels of EL-NE that persist 4 weeks after exacerbation support the hypothesis that each exacerbation may initiate a degradation process of ECM molecules that, in addition to chronic remodeling, may lead to accumulating structural and functional changes of the lung ECM, increased emphysema, and lung function limitation that accumulate with time. This outcome may also explain why patients with recurrent exacerbations have an accelerated decline in lung function.
We believe these findings are important for the following reasons:
(1) they demonstrate in a large, multicentric cohort that MMP-or NE-derived collagen and elastin turnover is increased at exacerbation in moderate to very severe COPD; (2) they strongly suggest that differences in ECM molecules at stable state and exacerbation are independent of age, sex, dyspnea, baseline lung function impairment, and the presence of comorbidities; (3) they indicate that exacerbations affect the ECM in a heterogeneous way (ie, although the degradation and formation of collagen type VI are increased, there is no change in collagen type III); (4) they infer that ECM neoepitopes could be used to identify the incidence of exacerbation and, potentially, its severity; and (5) they propose that the lung function decline subsequent to exacerbation could be induced, and thus potentially handled, by interventions directed toward ECM turnover at exacerbation. Thus, measurement of serum neoepitopes would allow better understanding of COPD pathogenesis and may enable a more focused and shorter proof-of-concept trial with fewer patients, thus assisting in innovative drug development. 25 We evidenced new associations of ECM neoepitopes at stable state and clinical outcome up to 2 years in COPD: formation fragments of collagen type III were increased in those at higher risk of exacerbation, whereas both formation of collagen type VI and its balance at stable state were predictive of mortality. An increase in collagen degradation biomarkers was also shown to be associated with disease progression, and the rate of this increase predicted survival in patients with idiopathic pulmonary fibrosis, 17 a progressive interstitial lung disease characterized by ECM remodeling. 26, 27 The results presented here suggest that protein fragments might provide an indirect measure of disease activity, particularly dynamic remodeling, of lung tissue also in COPD. Common to both diseases is the highly altered interaction between fibrogenesis and fibrinolysis leading to functional impairment of the lungs. 19 Therefore, it may be postulated that similar mechanisms of collagen degradation and formation leading to lung tissue remodeling may be shared between idiopathic pulmonary fibrosis and COPD. However, there is an urgent need to confirm these findings because they have the potential to improve and shorten the assessment of new treatment in COPD.
This study has a few limitations. We assessed circulating ECM turnover markers at stable state in two independent cohorts but did not evaluate dynamic changes of biomarkers in patients with stable disease longitudinally. Thus, although we could show an association of collagen and elastin biomarkers with exacerbation and outcome in COPD, we cannot exclude that the rate of change of these neoepitopes could have been even more informative to predict disease worsening and reduced survival. Further longitudinal studies are needed to elucidate if these neoepitopes are the cause or the result of disease pathogenesis.
Conclusions
Serologic biomarkers of ECM turnover were significantly associated with disease severity and clinically relevant outcomes in patients with COPD.
